June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Preclinical Evaluation of ENV905 (Difluprednate) Ophthalmic Implant: A Clinical Candidate for the Treatment of Pain and Inflammation Associated with Ocular Surgery
Author Affiliations & Notes
  • Andres Garcia
    Envisia Therapeutics, Research Triangle Park, NC
  • Rozemarijn S Verhoeven
    Envisia Therapeutics, Research Triangle Park, NC
  • Tyler Pegoraro
    Liquidia Technologies, Research Triangle Park, NC
  • Jeremy Hansen
    Envisia Therapeutics, Research Triangle Park, NC
  • Jinny Conley
    Envisia Therapeutics, Research Triangle Park, NC
  • Rilee Robeson
    Envisia Therapeutics, Research Triangle Park, NC
  • Brian C Gilger
    North Carolina State University, Raleigh, NC
  • Tomas Navratil
    Envisia Therapeutics, Research Triangle Park, NC
  • Benjamin Yerxa
    Envisia Therapeutics, Research Triangle Park, NC
  • Footnotes
    Commercial Relationships Andres Garcia, Envisia Therapeutics (E); Rozemarijn Verhoeven, Envisia Therapeutics (E); Tyler Pegoraro, Liquidia Technologies (E); Jeremy Hansen, Envisia Therapeutics (E); Jinny Conley, Envisia Therapeutics (E); Rilee Robeson, Envisia Therapeutics (E); Brian Gilger, Envisia Therapeutics (C); Tomas Navratil, Envisia Therapeutics (E); Benjamin Yerxa, Envisia Therapeutics (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5897. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Andres Garcia, Rozemarijn S Verhoeven, Tyler Pegoraro, Jeremy Hansen, Jinny Conley, Rilee Robeson, Brian C Gilger, Tomas Navratil, Benjamin Yerxa; Preclinical Evaluation of ENV905 (Difluprednate) Ophthalmic Implant: A Clinical Candidate for the Treatment of Pain and Inflammation Associated with Ocular Surgery. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5897. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Topical corticosteroids are widely used in the treatment of inflammation and pain following ocular surgery. However, topical therapies possess several shortcomings including frequent dosing and low patient adherence. We evaluated the efficacy, duration of action, and tolerability of ENV905 (difluprednate) Ophthalmic Implant for the treatment of inflammation and pain associated with ocular surgery. ENV905 is a biocompatible polymer drug delivery system designed for administration during ocular surgery, providing therapeutic concentrations of difluprednate over 4 weeks in a tapering manner.

Methods: We used PRINT® technology to fabricate solid implants for either subconjunctival (SC) or intracameral (IC) delivery. A post-operative inflammation model was used to evaluate the efficacy and safety of ENV905 in albino rabbits over a period of 4 weeks. Animals (2-4/group) received a 2.7 mm corneal incision and ENV905 or placebo administration on Day 1, and anterior chamber paracentesis via a 30G needle on days 9, 15 and 22; Durezol® QID was used as a positive control. Animals were observed for general tolerability and were examined for ocular inflammation using slit lamp ophthalmoscopy and Hackett-McDonald scoring.

Results: ENV905 was successfully administered via either SC or IC injection using a custom applicator, and no adverse effects were noted during the study. SC implants remained at the injection site, IC implants nestled in the inferior iridocorneal angle following dosing, and no implants were visible upon completion of the study. Suppression of ocular inflammation for ENV905 was marked compared with placebo, and was superior or equivalent to that observed with QID Durezol at all time points throughout the 4 week period.

Conclusions: ENV905 delivered via a single SC or IC administration in rabbits was well tolerated and demonstrated a robust reduction in ocular inflammation over 4 weeks. The results from this study show that ENV905 provides a sustained therapeutic effect following a single dose, thus potentially bypassing the need for topical therapies requiring multiple daily instillations. By resolving low patient compliance and eliminating the peaks and troughs in drug concentration, sustained drug delivery of ocular difluprednate may further improve the overall control of post-operative inflammation and pain.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×